CALCIUM Drug Patent Profile
✉ Email this page to a colleague
When do Calcium patents expire, and when can generic versions of Calcium launch?
Calcium is a drug marketed by Amneal Pharms, Chartwell Rx, Heritage Pharms Inc, Hikma, Invagen Pharms, Lotus Pharm Co Ltd, Lupin Ltd, Nostrum Labs Inc, Square Pharms, Suven Pharms, Chartwell Molecular, Padagis Us, Am Regent, Amneal, Extrovis, Intl Medication Sys, Medefil Inc, Somerset, Hospira, Bausch, Abbott, Abraxis Pharm, Lilly, B Braun Medical Inc, Fresenius Kabi Usa, Nivagen Pharms Inc, and Hq Spclt Pharma. and is included in thirty-three NDAs. There are two patents protecting this drug.
The generic ingredient in CALCIUM is calcium gluconate. There are two hundred and eighty-two drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the calcium gluconate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Calcium
A generic version of CALCIUM was approved as calcium gluconate by FRESENIUS KABI USA on June 15th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CALCIUM?
- What are the global sales for CALCIUM?
- What is Average Wholesale Price for CALCIUM?
Summary for CALCIUM
| US Patents: | 0 |
| Applicants: | 27 |
| NDAs: | 33 |
| Drug Prices: | Drug price information for CALCIUM |
| Drug Sales Revenues: | Drug sales revenues for CALCIUM |
| DailyMed Link: | CALCIUM at DailyMed |
